We look forward to sharing additional Phase 1/2 data next week at the Muscular Dystrophy Association's annual meeting and ...
Founded in late 2024, ALTx Therapeutics has come out of stealth mode with plans to develop therapies to target the alternative lengthening of telomeres (ALT) pathway in cancer cells. Telomeres are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results